Innovative automation solutions for medical device and diagnostic industries
We offer automation solutions for
More effective healthcare globally
Our mission is to find the best solutions for our customers to manufacture rapid diagnostics tests (point of care, POC) and medical devices in an efficient and high-quality manner.
Our approach is similar to the one adopted in the electronics industry, known for tremendous productivity.
Our unique desktop automation approach takes a smaller footprint compared to traditional automation, saving valuable space in your production facilities.
Our modular production automation solutions are easy to reconfigure to meet your changing needs, whether you need to redesign the process or replace your entire product. We build our customer-specific solutions on a standard platform, which brings you even more benefit in terms of lead time and validation.
Our scalable solutions allow you to invest first in the critical processes and scale your production as the volume grows.
With our solution, you can increase production by multiplying processes that have become a bottleneck for production capacity.
Latest News & Articles
Ginolis has undergone a significant internal transformation, prompting a strategic reassessment of our brand identity to align with our current operation and customer segments. This evolution has strengthened our position in the market and enabled us to meet our customers’ evolving needs.
Ginolis is pleased to announce the appointment of Chris Buhlmann as our General Manager for North America.
BBI Solutions chose Ginolis BBI Solutions has served the global diagnostics industry for over 50 years, as a leading developer and
Kauko Väinämö has been appointed as CEO of Ginolis Oy from September 1, 2022. Kauko has more than 30 years of solid
A global pandemic presents many challenges for diagnostic device manufacturers, especially those dependent on traditional manufacturing processes that are not
Ginolis Ltd. and CELLINK AB have entered into an agreement where CELLINK acquires 100 per cent of Ginolis shares. With
We can answer all your questions!